Meeting
2019 ASCO Annual Meeting
A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).
Authors
Vatche Tchekmedyian
Memorial Sloan Kettering Cancer Center, NY, NY
Vatche Tchekmedyian , Eric Jeffrey Sherman , Lara Dunn , James Vincent Fetten , Loren S. Michel , Anuja Kriplani , Luc Morris , Irina Ostrovnaya , Nora Katabi , Sofia Haque , Crystal Tran , Julian Azar , David G. Pfister , Alan Loh Ho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT03172624
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6084)
DOI
10.1200/JCO.2019.37.15_suppl.6084
Abstract #
6084
Poster Bd #
73
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang
Poster
2021 ASCO Annual Meeting
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).
First Author: Michael B. Atkins
Poster
2017 ASCO Annual Meeting
Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).
First Author: Elisa A. Rozeman
Poster
2023 ASCO Annual Meeting
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
First Author: Bradley Alexander McGregor